Press / Medias

Christensenella: the key to unlocking gut microbiome-based drug discovery?

Jan 2, 2019

LNC Therapeutics recently signed an exclusive license agreement with Cornell University for its Christensenella patent, which covers a recently discovered family of gut bacteria considered to have the potential to unlock a wide range of therapeutic applications for conditions such as obesity and other metabolic diseases. Will this form the foundation for the first drugs using microbiome bacteria? Sally Turner finds out.

 

Clic here to read the full article

In the same category

Press / Medias

YSOPIA Bioscience : Restaurer le microbiome pour soigner !

Apr 14, 2022

more +
Press / Medias

Seventure Partners : Une croissance continue dans le secteur du microbiome en 2021 qui va se...

Mar 15, 2022

more +
Press / Medias

Inria partage son expertise avec la biotech bordelaise Ysopia

Feb 2, 2022

more +

YSOPIA Bioscience © 2022 - all rights reserved terms and conditions